Antibody stops responding to virus over time: Covid vaccine under scrutiny

The study suggests that antibodies, a marker of exposure to the coronavirus, may not be lasting in all people

Coronavirus
eople who tested positive but didn’t show symptoms of Covid-19 appeared to lose antibodies more often than those who suffered noticeable effects. (Bloomberg)
Eric Pfanner | Bloomberg
1 min read Last Updated : Oct 27 2020 | 8:00 AM IST
Antibody responses to the coronavirus may diminish over time, according to a study that showed the natural defenses waning in Britons who’d previously been exposed.

Among 365,000 randomly selected U.K. adults who tested themselves at home, 4.4% had antibodies in September, compared with 6% in June, according to research published Tuesday by Imperial College London and polling service Ipsos MORI.

The study suggests that antibodies, a marker of exposure to the coronavirus, may not be lasting in all people who have been infected, adding to other research indicating that immunity may be finite.

A small but growing number of patients have fallen ill with Covid-19 twice, and it’s not clear how long antibody protection from any vaccine would last. Some protective shots under development also aim to stimulate so-called T-cells that can fight off viruses.

People who tested positive but didn’t show symptoms of Covid-19 appeared to lose antibodies more often than those who suffered noticeable effects of the disease, the study showed.


One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus TestsCoronavirus VaccineAntibiotics

Next Story